In this text, Mary Rosenzweig, Country director Denmark at Quantify Research, gives her perspectives on the changing landscapes in market access and real-world evidence in Denmark and the keys to successful value demonstration of new innovative medicines.
Innovative medicines require an innovative approach
As the costs of healthcare rise globally, Denmark is working hard to keep healthcare spending under tight control in unison with payers everywhere. Hence, great attention is given to decisions concerning the recommendations of medicine in Danish hospitals. New and existing medicines face increasing requirements for documentation surrounding the benefit to the patient. For this reason, high quality clinical documentation and health economic analyses are in increasing demand.
In Denmark, we have observed an increase in the innovation of new medicines targeting small patient populations or patients with rare diseases. According to the Danish Association of the Pharmaceutical Industry (Lif), more than 42% of all new medicines in development are personalized medicines, and notably, 73% of all cancer medicines in development are personalized medicines (https://www.lif.dk/fakta-analyse/life-science-i-tal/).
In light of these developments, traditional methods to assess the value of medicines may need to be complemented by approaches that can accommodate larger uncertainty around treatment effects and health economic impact. Quantify has extensive experience in providing strategic support, economic modelling, HTA submissions and value demonstrations for innovative treatments for rare diseases in the Nordics and in Denmark; this is an area I really look forward keep developing in Danish context.